Mainz Biomed N.V. announced that it received formal notice from The Nasdaq Stock Market LLC on January 23, 2025, confirming its regained compliance with the minimum stockholders’ equity requirement for continued listing.
The company had previously received confirmation that it had regained compliance with the minimum bid price requirement. With these confirmations, Mainz Biomed is now in full compliance with all Nasdaq continued listing requirements.
This achievement ensures the company's continued listing and trading on The Nasdaq Capital Market, removing a significant regulatory concern that had been addressed through actions such as the recent reverse stock split.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.